Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide and Lanthanum Carbonate for Phosphorus Homeostasis in Healthy Volunteers
NCT03136705Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Feb 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nicotinamide in chronic kidney disease (CKD) (4 arms), sponsored by Northwestern University. Primary endpoint: Change in Intact Fibroblast Growth Factor 23 at 3 weeks. Started Feb 2016; status: completed.
02
Drugs
nicotinamide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03136705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136705.